
Congress on the Brink of Disrupting the PBM Market
During much of 2024, the prevailing view in Washington was that some policies related to pharmacy benefit managers (PBMs) would be included in the end-of-year continuing resolution.
During much of 2024, the prevailing view in Washington was that some policies related to pharmacy benefit managers (PBMs) would be included in the end-of-year continuing resolution.
Delinking would lead to higher costs for patients and taxpayers and put more money in the pockets of brand drug manufacturers.
Pharmacy benefit managers (PBMs) are a popular Congressional target of late.
As Congress stumbles toward a government shutdown, health policy legislation continues to simmer in the background.
In January, the 21-year monopoly for AbbVie’s blockbuster drug Humira (adalimumab) came to an end with the launch of Amjevita, Amgen’s biosimilar adalimumab.